Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The polo-like kinase PLK2 has recently been identified as a potential theranostic marker in the management of chemotherapy sensitive cancers. The methylation status of the PLK2 CpG island varies with sensitivity to paclitaxel and platinum in ovarian cancer cell lines. Importantly, extrapolation of these in vitro data to the clinical setting confirms that the methylation status of the PLK2 CpG island predicts outcomes in patients treated with carboplatin and paclitaxel chemotherapy. A second cell cycle regulator, p57Kip2, is also subject to epigenetic silencing in carboplatin resistance in vitro and in vivo, emphasising that cell cycle regulators are important determinants of sensitivity to chemotherapeutic agents and providing insights into the phenomenon of collateral drug sensitivity in oncology. Understanding the mechanistic basis and identification of robust biomarkers to predict collateral sensitivity may inform optimal use of chemotherapy in patients receiving multiple lines of treatment.

Original publication

DOI

10.18632/oncotarget.332

Type

Journal article

Journal

Oncotarget

Publication Date

01/2012

Volume

3

Pages

78 - 83

Keywords

Animals, Biomarkers, Tumor, Carcinoma, Drug Resistance, Neoplasm, Epigenesis, Genetic, Female, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Humans, Ovarian Neoplasms, Protein-Serine-Threonine Kinases